drugset / Trial / NCT05516589
Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCC
NaSingle-groupOpen-labelTreatment
Summary
To explore the efficiency and safety of TP chemotherapy, tislelizumab, combined with afatinib as a new neoadjuvant treatment regimen for patients with resectable HNSCC.
Timeline
- Start
- 2022-09-12
- Primary completion
- 2023-10-29
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 30 mg | Oral |
| Subject | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | 200 mg | Intravenous |